Adynxx, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADYX research report →
Companywww.adynxx.com
Adynxx, Inc. , a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain.
- CEO
- Richard Orr
- IPO
- 1998
- Employees
- 6
- HQ
- San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $581
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 1.67
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 22.38%
- Op Margin
- -238.99%
- Net Margin
- -379.83%
- ROE
- -70.38%
- ROIC
- -63.78%
Growth & Income
- Revenue
- $2.22M · 9.76%
- Net Income
- $-8,417,000 · 67.26%
- EPS
- $-10.26 · 71.45%
- Op Income
- $-5,296,000
- FCF YoY
- 10.52%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -8.54
- Avg Volume
- 168
Get TickerSpark's AI analysis on ADYX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 22, 19 | FLESHER GREGORY J. | other | 0 |
| May 29, 19 | GONZALEZ DINA | other | 26,358 |
| May 29, 19 | GONZALEZ DINA | other | 1,577 |
| May 29, 19 | GONZALEZ DINA | other | 1,577 |
| May 3, 19 | TPG Group Holdings (SBS) Advisors, Inc. | other | 0 |
| May 3, 19 | DP VIII Associates, L.P. | other | 0 |
| May 3, 19 | Domain Partners VIII, L.P. | other | 0 |
| May 3, 19 | ABEL STAN E | other | 54,117 |
| May 3, 19 | ABEL STAN E | other | 27,940 |
| May 3, 19 | ABEL STAN E | other | 198 |
Our ADYX Coverage
We haven't published any research on ADYX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ADYX Report →